Stem cell secretome plus magnetic brain stimulation for movement recovery after ischemic stroke
Tests stem cell secretome with magnetic stimulation for movement recovery after ischemic stroke.
Plain-language title generated from the registry record
Registry title: MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke
Key facts
- Where
- Makassar, IndonesiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 75 years old?
Source: NCT07874269, who can take part
Where in Indonesia
- Inggit Medical CentreMakassar, IndonesiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jumraini Tammasse
- Trial code
- NCT07874269
- Record updated
- 21 October 2026
- Original description
This randomized, double-blind, controlled clinical trial evaluates the effectiveness and safety of combined mesenchymal stem cell (MSC) secretome and repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute ischemic stroke. Participants will be randomized to either an intervention group receiving intravenous MSC secretome combined with high-frequency ipsilesional rTMS or a control group receiving placebo infusion and sham rTMS. The intervention is administered once weekly for 8 weeks. The primary outcome is change in motor function measured using the Fugl-Meyer Motor Scale. Secondary outcomes include changes in quantitative electroencephalography biomarkers, including sensorimotor rhythm, delta-theta-to-alpha-beta ratio, and beta coherence, as well as spasticity assessed using the Modified Ashworth Scale and treatment-related adverse events.Read full original descriptionShow less
Effectiveness of Combined Mesenchymal Stem Cell Secretome and Repetitive Transcranial Magnetic Stimulation on Motor Recovery and Quantitative Electroencephalography Biomarkers in Patients With Subacute Ischemic Stroke: A Double-Blind Randomized Controlled Trial
This randomized, double-blind, controlled clinical trial evaluates the effectiveness and safety of combined mesenchymal stem cell (MSC) secretome and repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute ischemic stroke. Participants will be randomized to either an intervention group receiving intravenous MSC secretome combined with high-frequency ipsilesional rTMS or a control group receiving placebo infusion and sham rTMS. The intervention is administered once weekly for 8 weeks. The primary outcome is change in motor function measured using the Fugl-Meyer Motor Scale. Secondary outcomes include changes in quantitative electroencephalography biomarkers, including sensorimotor rhythm, delta-theta-to-alpha-beta ratio, and beta coherence, as well as spasticity assessed using the Modified Ashworth Scale and treatment-related adverse events.
Inclusion: Age 30 to 75 years; Diagnosis of subacute ischemic stroke, 1 to 6 months after stroke onset; First-ever ischemic stroke; Ischemic stroke confirmed by magnetic resonance imaging (MRI) or computed tomography (CT); Able to undergo repetitive transcranial magnetic stimulation (rTMS) therapy.
Exclusion: History of active seizures; Severe systemic disease that may affect participant safety or interfere with study participation; Presence of intracranial metal or implanted devices that are contraindications to rTMS.